KR970704677A - 의약으로서의 벤조일구아니딘 유도체(Benzovlguanidine Derivatives as Medicaments) - Google Patents

의약으로서의 벤조일구아니딘 유도체(Benzovlguanidine Derivatives as Medicaments) Download PDF

Info

Publication number
KR970704677A
KR970704677A KR1019970700726A KR19970700726A KR970704677A KR 970704677 A KR970704677 A KR 970704677A KR 1019970700726 A KR1019970700726 A KR 1019970700726A KR 19970700726 A KR19970700726 A KR 19970700726A KR 970704677 A KR970704677 A KR 970704677A
Authority
KR
South Korea
Prior art keywords
alkyl
carbamoyl
dihalo
mono
hydroxy
Prior art date
Application number
KR1019970700726A
Other languages
English (en)
Inventor
아추시 쿠노
히로아키 미주노
쿠미 야마사키
요시카주 이노우에
Original Assignee
후지야마 아키라
후지사와 야꾸힝 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9415852A external-priority patent/GB9415852D0/en
Priority claimed from GB9422830A external-priority patent/GB9422830D0/en
Priority claimed from GBGB9505231.2A external-priority patent/GB9505231D0/en
Application filed by 후지야마 아키라, 후지사와 야꾸힝 고교 가부시키가이샤 filed Critical 후지야마 아키라
Publication of KR970704677A publication Critical patent/KR970704677A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/12—One of the condensed rings being a six-membered aromatic ring the other ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

본 발명은 약제로서 유용한 하기 식의 구아니딘 유도체 또는 그의 약제학적으로 허용되는 염에 관한 것이다 :
상기 식에서, R1은 수소, 하이드록시(저급)알킬, 보호된 하이드록시(저급)알킬, 아실(저급)알콕시, 아실(저급)알케닐, 또는 아실이고, R2는 아르(저급)알케닐; 적절한 두개의 치완체로 치환된 아릴; 각각 적절한 치환체를 가진 인데닐, 인다닐, 디하이드로벤조사이클로헵테닐, 디(또는 테트라 또는 헥사 또는 옥타 또는 데카)하이드로나프틸, 사이클로펜테닐, 디하이드로티에닐, 디하이드로푸릴 또는 헤테로디사이클릭 그룹; 저급 알킬티에닐; 모노(또는 디) 할로티에닐; 모노(또는 디 또는 트리)할로(저급)알킬티에닐; 아실티에닐; 할로푸릴; 또는 모노(또는 디 또는 트리)할로(저급)알킬푸릴이다.

Description

의약으로서의 벤조일구아니딘 유도체(Benzovlguanidine Derivatives as Medicaments)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. 하기 일반식의 화합물 및 약제학적으로 허용되는 그의 염:
    상기 식에서, R1은 수소, 하이드록시(저급)알킬, 보호된 하이드록시(저급)알킬, 아실(저급)알콕시, 아실(저급)알케닐, 또는 아실이고, R2는 아르(저급)알케닐; 적절한 두개의 치완체로 치환된 아릴; 각각 적절한 치환체를 가진 인데닐, 인다닐, 디하이드로벤조사이클로헵테닐, 디(또는 테트라 또는 헥사 또는 옥타 또는 데카)하이드로나프틸, 사이클로펜테닐, 디하이드로티에닐, 디하이드로푸릴 또는 헤테로디사이클릭 그룹; 저급 알킬티에닐; 모노(또는 디) 할로티에닐; 모노(또는 디 또는 트리)할로(저급)알킬티에닐; 아실티에닐; 할로푸릴; 또는 모노(또는 디 또는 트리)할로(저급)알킬푸릴이다.
  2. 제1항에 있어서, 상기 식에서, R1이 수소; 하이드록시(저급)알킬; 아실옥시(저급)알킬;〔디(저급)알킬아미노(저급)알킬〕카바모일(저급)알콕시;〔디(저급)알킬아미노(저급)알킬, 헤테로사이클릭(저급)알킬〕, 디하이드록시(저급)알킬 또는 저급 알킬피페라지닐을 가질 수 있는 카바모일; 또는 저급 알킬을 가질 수 있는 헤테로사이클릭카보닐이며, R2가 페닐(저급)알케닐; 할로겐, 저급 알콕시, 하이드록시, 저급 알킬 및 모노(또는 디 또는 트리)할로(저급)알킬로 구성된 그룹중에서 선택된 두개의 치환제에 의해 치환된 페닐; 각각 옥소, 하이드록시이미노(저급)알킬, 보호된 하이드록시아미노(저급)알킬, 하이드록시(저급)알킬, 보호된 하이드록시(저급)알킬, 모노(또는 디 또는 트리)할로(저급)알킬, 할로겐, 저급 알킬렌, 저급 알킬, 저급 알콕시(저급)알킬 및 시아노로 구성된 그룹중에서 선택된 1 내지 3개의 치환체를 가질 수 있는 인데닐, 인다닐, 디하이드로벤조사이클로헵테닐, 디(또는 테트라 또는 헥사 또는 옥타 또는 데카)하이드로나프틸, 사이클로펜테닐, 디하이드로티에닐, 디하이드로푸릴, 벤조푸릴, 디하이드로벤조부필, 벤조피라닐, 저급알킬렌디옥시페닐, 퀴놀릴, 이소퀴놀릴, 퀴녹살리닐, 벤족사졸릴, 이미다조피리딜, 벤조티에닐 또는 인돌릴; 저급 알킬티에닐; 모노(또는 디)할로티에닐; 〔디할로(저급)알킬〕티에닐; 저금 알카노일티에닐; 설파모일티에닐; 할로푸릴; 또는 〔디할로(저급)알킬〕푸릴인 화합물.
  3. 제1항에 있어서, R1은 수소; 하이드록시(저급)알킬; 아실옥시(저급)알킬;〔디(저급)알킬아미노(저급)알킬〕카바모일(저급)알콕시;〔디(저급)알킬아미노(저급)알킬〕카바모일(저급)알케닐; 디아미노9저급)알킬리덴, 디(저급)알킬아미노(저급)알킬, 모르폴리닐(저급)알킬, 피롤리디닐(저급)알킬, 피페리딜(저급)알킬, 디하이드록시(저급)알킬 또는 저급 알킬피페라지닐을 가질 수 잇는 카바모일; 또는 저급 알킬을 가질 수 있는 피폐라지닐가보닐이며, R2가 페닐(저급)알케닐; 할로겐, 저급 알콕시, 하이드록시, 저급 알킬 및 모노(또는 디 도는 트리)할로(저급)알킬로 구성된 그룹중에서 선택된 두개의 치환체에 의해 치환된 페닐; 각각 옥소, 하이드록시이미노(저급)알킬, 아실옥시이미노(저급)알킬), 하이드록시(저급)알킬, 아실옥시(저급)알킬, 모노(또는 디 또는 트리)할로(저급)알킬, 할로겐, 저급 알킬렌, 저급 알킬, 저급 알콕시(저급)알킬 및 시아노로 구성된 그룹중에서 선택된 1 또는 2개의 치환체를 가질 수 있는 인데닐, 인다닐, 디하이드로벤조사이클로헵테닐, 디(또는 테트라 또는 헥사 또는 옥타 또는 테카)하이드로나프틸, 사이클로펜테닐, 디하이드로티에닐, 디하이드로푸릴, 벤조푸릴, 디하이드벤조푸릴, 벤조피라닐, 저급 알킬렌디옥시페닐, 퀴놀릴, 이소퀴놀릴, 퀴녹살리닐, 벤족사졸릴, 이미다조피리딜, 벤조티에닐 또는 인돌릴; 저급 알킬티에닐; 모노(또는 디)할로티에닐; 〔디할로(저급)알킬〕티에닐; 저급 알카노일티에닐; 설파모일티에닐; 할로푸릴; 또는 〔디할로(저급)알킬〕푸릴인 화합물.
  4. 제3항에 있어서, R1은 수소; 하이드록시(저급)알킬; 아실옥시(저급)알킬;〔디(저급)알킬아미노(저급)알킬〕카바모일(저급)알콕시;〔디(저급)알킬아미노(저급)알킬〕카바모일(저급)알케닐; 디아미노(저급)알킬리덴카바모일; 〔디(저급)알킬아미노(저급)알킬〕카바모일; 〔모르폴리닐(저급)알킬〕카바모일;〔저급 알킬피페라지닐〕카바모일; 또는 저급 알킬피페라지닐〕카바모일; 도는 저급 알킬피페라지닐카보닐이며, R2가 페닐(저급)알케닐; 디할로페닐; 디(저급)알콕시페닐; 디하이드록시페닐; 디(저급)알킬페닐; 비스(트리할로(저급)알킬)페닐; 인데닐; 옥소를 가질 수 있는 인다닐; 디하이드로벤조사이클로헵테닐; 하이드록시이미노(저급)알킬, 하이드록시(저급)알킬, 디할로(저급)알킬 또는 저급 알콕시(저급)알킬을 가질 수 있는 사이클로펜테닐; 시아노를 가질 수 있는 디하이드로티에닐; 시아노를 가질 수 있는 디하이드로푸릴; 저급알킬, 할로겐 또는 디할로(저급)알킬을 가질 수 있는 벤조푸릴; 디하이드로벤조푸릴; 저급알킬, 저급 알킬렌 및 할로겐으로 구성된 그룹중에서 선택된 하나 또는 두개으 치환체를 가질 수 있는 이미다조피리딜; 할로겐 또는 디할로(저급)알킬을 가질 수 있는 벤조티에닐; 저급 알킬을 가질 수 있는 인돌릴; 저급 알킬티에닐; 모노(또는 디)할로티에닐;〔디할로(저급)알킬〕티에닐; 저급 알킬을 가질 수 있는 이미다조피리딜; 할로겐 또는 디할로(저급)알킬을 가질 수 있는 벤조티에닐; 저급 알킬을 가질 수 있는 인돌릴; 저급 알킬티에닐; 모노(또는 디)할로티에닐;〔디할로(저급)알킬〕티에닐;저급 알카노일티에닐; 설파모일티에닐; 할로푸릴, 또는 〔디할로(저급)알킬〕푸릴인 화합물.
  5. 제4항에 있어서, R2가 페닐(저급)알케닐; 디할로페닐, 디(저급)알콕시페닐, 디하이드록시페닐, 디(저급)알킬페닐, 비스(트리할로(저급)알킬)페닐, 인데닐, 옥소인다닐, 디하이드로벤조사이클로헵테닐, 디하이드로나프틸, 〔하이드록시이미노(저급)알킬〕디하이드로나프틸, 〔하이드록시(저급)알킬〕디하이드로나프틸, 〔디할로(저급)알킬〕디하이드로나프틸, 〔저급 알콕시(저급)알킬〕디하이드로나프틸, 옥타하이드로나프닐, 시아노사이클로펜테닐, 시아노디하드로티에닐, 시아노디하이드로 푸릴, 벤조푸릴, 저급 알킬벤조푸릴, 할로벤조푸릴, 〔디할로(저급)알킬〕펜조푸릴, 디하이드로벤조푸릴, 벤조피라닐, 디(저급)알킬벤조피라닐, 저급 알킬렌벤조피라닐, 할로벤조피라닐, 메틸렌디옥시페닐, 퀴놀릴, 이소퀴놀릴, 퀴녹살리닐, 벤족사졸릴, 저급 알킬 이미다조피리딜, 벤조티에닐, 할로벤조티에닐, 디할로(저급)알킬벤조티에닐, 인돌릴, 저급 알킬인돌릴, 저급 알킬티에닐, 모노(또는 디)할로티에닐,〔디할로(저급)알킬〕티에닐, 저급 알카노일티에닐, 설파모일티에닐, 할로푸릴, 또는 〔디할로(저급)알킬〕푸릴인 화합물.
  6. 제5항에 있어서, R1이〔피롤리디닐(저급)알킬〕카바모일, 〔피페리딜(저급)알킬〕카바모일, 〔디(저급)알킬아미노(저급)알킬〕카바모일이며, R2가 디할로티에닐인 화합물.
  7. 제5항에 있어서, R1이〔디(저급)알킬아미노(저급)알킬〕카바모일 또는〔저급 알킬피페라지닐〕카바모일이며, R2가 〔디할로(저급)알킬〕티에닐인 화합물.
  8. 일반식(Ⅱ)의 화합물 또는 그의 카복실 그룹에서의 반응성 유도체 또는 그의 염을 하기 구조식(Ⅲ)의 화합물 또는 그의 이미노 그룹에서의 반응성 유도체 도는 그의 염과 반응시킴을 특징으로 하는 하기 일반식(Ⅰ)의 화합물 또는 그의 염을 제조하는 방법 :
    상기 식에서, R1은 수소, 하이드록시(저급)알킬, 보호된 하이드록시(저급)알킬, 아실(저급)알콕시, 아실(저급)알케닐, 또는 아실이고, R2는 아르(저급)알케닐; 적절한 두개의 치완체로 치환된 아릴; 각각 적절한 치환체(들)을 가질 수 있는 인데닐, 인다닐, 디하이드로벤조사이클로헵테닐, 디(또는 테트라 또는 헥사 또는 옥타 또는 데카)하이드로나프틸, 사이클로펜테닐, 디하이드로티에닐, 디하이드로푸릴 또는 헤테로디사이클릭 그룹; 저급 알킬티에닐; 모노(또는 디) 할로티에닐; 모노(또는 디 또는 트리)할로(저급)알킬티에닐; 아실티에닐; 할로푸릴; 또는 모노(또는 디 또는 트리)할로(저급)알킬푸릴이다.
  9. 활성 성분으로서 제1항에서 청구한 화합물 또는 그의 약제학적으로 허용되는 염을 약제학적으로 허용되는 담체와의 혼합물로서 함유하는 약제학적 조성물.
  10. 제1항에서 청구한 화합물 또는 그의 약제학적으로 허용되는 염의 세포내에서의 Na+/H+교환에 대한 억제제로서의 용도.
  11. 제1항에서 청구한 화합물 또는 그의 약제학적으로 허용되는 염을 인간 또는 동물에 투여하여 심장 혈관 질병, 뇌혈관 질병, 신장 질병, 동맥 경화증 또는 쇼크를 예방 또는 치료하는 방법.
  12. 제1항에서 청구한 화합물 또는 그의 약제학적으로 허용되는 염을 약제학적으로 허용되는 담체화 혼합시킴을 포함하는 약제학적 조성물의 제조 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970700726A 1994-08-05 1995-07-25 의약으로서의 벤조일구아니딘 유도체(Benzovlguanidine Derivatives as Medicaments) KR970704677A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9415852A GB9415852D0 (en) 1994-08-05 1994-08-05 Guanidine derivatives
GB9415852.4 1994-08-05
GB9422830A GB9422830D0 (en) 1994-10-11 1994-10-11 Guanidine derivatives
GB9422830.1 1994-11-11
GB9505231.2 1995-03-15
GBGB9505231.2A GB9505231D0 (en) 1995-03-15 1995-03-15 Guanidine derivatives

Publications (1)

Publication Number Publication Date
KR970704677A true KR970704677A (ko) 1997-09-06

Family

ID=27267318

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970700726A KR970704677A (ko) 1994-08-05 1995-07-25 의약으로서의 벤조일구아니딘 유도체(Benzovlguanidine Derivatives as Medicaments)

Country Status (10)

Country Link
US (1) US5968985A (ko)
EP (1) EP0773927A2 (ko)
JP (1) JP3473023B2 (ko)
KR (1) KR970704677A (ko)
CN (1) CN1070173C (ko)
BR (1) BR9502471A (ko)
CA (1) CA2196763A1 (ko)
IL (1) IL114670A0 (ko)
TW (1) TW426658B (ko)
WO (1) WO1996004241A2 (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19531138A1 (de) * 1995-08-24 1997-02-27 Merck Patent Gmbh Alkenyl-benzoylguanidin-Derivate
DE19540995A1 (de) * 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19542306A1 (de) * 1995-11-14 1997-05-15 Hoechst Ag Sulfonylamino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
PL316439A1 (en) * 1995-11-20 1997-05-26 Hoechst Ag Novel substituted derivatives of benzoyloguanidine, method of obtaining them, their application in production of pharmaceutic and diagnostic agents and pharmaceutic agent as such
PL316438A1 (en) * 1995-11-20 1997-05-26 Hoechst Ag Novel substituted derivatives of benzoyloguanidine, method of obtaining them, their application in production of pharmaceutic and diagnostic agents and pharmaceutic agent as such
GB9600063D0 (en) * 1996-01-03 1996-03-06 Fujisawa Pharmaceutical Co Guaridine derivatives
JPH11502876A (ja) * 1996-01-26 1999-03-09 藤沢薬品工業株式会社 グアニジン誘導体
DE19622222A1 (de) * 1996-06-03 1997-12-04 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide
EP0825187A1 (en) * 1996-08-22 1998-02-25 Takeda Chemical Industries, Ltd. Condensed pyridazinyl guanidines, their production and use
AUPO903897A0 (en) * 1997-09-08 1997-10-02 Commonwealth Scientific And Industrial Research Organisation Organic boronic acid derivatives
DE19837069C1 (de) 1998-08-17 2000-01-05 Bayer Ag Substituierte Zimtsäuren und Zimtsäureester, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von substituierten Indanoncarbonsäureestern
JP2002542291A (ja) 1999-04-23 2002-12-10 ブリストル−マイヤーズ スクイブ カンパニー ジ環式アシルグアニジン・ナトリウム／プロトン交換抑制剤および方法
US6706732B1 (en) 1999-06-03 2004-03-16 Takeda Chemical Industries, Ltd. Nasal preparation of guanidinoimino quinoline derivatives
GB2351081A (en) * 1999-06-18 2000-12-20 Lilly Forschung Gmbh Pharmaceutically active imidazoline compounds and analogues thereof
JPWO2004004701A1 (ja) * 2002-07-09 2005-11-04 アステラス製薬株式会社 頻尿および尿失禁治療剤
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
US7622492B2 (en) 2005-08-31 2009-11-24 Hoffmann-La Roche Inc. Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase
CN100371328C (zh) * 2006-01-19 2008-02-27 中国药科大学 取代苯甲酰基胍衍生物、其制备方法及其医药用途
CN103102251B (zh) 2006-11-02 2016-01-20 三菱瓦斯化学株式会社 放射线敏感性组合物
JP5446118B2 (ja) * 2007-04-23 2014-03-19 三菱瓦斯化学株式会社 感放射線性組成物
CN104262204A (zh) * 2014-09-22 2015-01-07 江苏天晟药业有限公司 一种水杨酸胍类化合物的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ284456B6 (cs) * 1992-02-15 1998-12-16 Hoechst Aktiengesellschaft Aminosubstituované benzoylguanidiny, způsob jejich přípravy, jejich použití jako léčiv a léčivo, které je obsahuje
EP0556673B1 (de) * 1992-02-15 1997-09-17 Hoechst Aktiengesellschaft Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
ATE139526T1 (de) * 1992-02-15 1996-07-15 Hoechst Ag 3,5-substituierte benzoylguanidine, mit antiarrythmischer wirkung und inhibierender wirkung auf die proliferationen von zellen
DE59304166D1 (de) * 1992-07-01 1996-11-21 Hoechst Ag 3,4,5-Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
TW250479B (ko) * 1992-12-15 1995-07-01 Hoechst Ag
DE59306029D1 (de) * 1992-12-16 1997-05-07 Hoechst Ag 3,5-Substituierte Aminobenzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0604852A1 (de) * 1992-12-28 1994-07-06 Hoechst Aktiengesellschaft 2,4-Substituierte 5-(N-substituierte-Sulfamoyl)-Benzoylguanidine, als Antiarrythmika, Inhibitoren der Proliferationen von Zellen, und Inhibitoren des Natrium-Protonen-Antiporters
DE59403818D1 (de) * 1993-02-20 1997-10-02 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, als Inhibitoren des zellulären Na+/H+-Austauschs oder als Diagnostikum sowie sie enthaltendes Medikament
IL109570A0 (en) * 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
DE4318658A1 (de) * 1993-06-04 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4318756A1 (de) * 1993-06-05 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4325822A1 (de) * 1993-07-31 1995-02-02 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4327244A1 (de) * 1993-08-13 1995-02-16 Hoechst Ag Harnstoffsubstituierte Benzoylguandine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4328869A1 (de) * 1993-08-27 1995-03-02 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Also Published As

Publication number Publication date
US5968985A (en) 1999-10-19
EP0773927A2 (en) 1997-05-21
TW426658B (en) 2001-03-21
CN1158606A (zh) 1997-09-03
IL114670A0 (en) 1995-11-27
JPH10503770A (ja) 1998-04-07
AU697748B2 (en) 1998-10-15
WO1996004241A3 (en) 1996-06-20
BR9502471A (pt) 1996-05-21
WO1996004241A2 (en) 1996-02-15
CA2196763A1 (en) 1996-02-15
AU2991695A (en) 1996-03-04
JP3473023B2 (ja) 2003-12-02
CN1070173C (zh) 2001-08-29

Similar Documents

Publication Publication Date Title
KR970704677A (ko) 의약으로서의 벤조일구아니딘 유도체(Benzovlguanidine Derivatives as Medicaments)
RU2220143C2 (ru) Оптически активные производные бензопирана, фармацевтическая композиция на их основе и способ лечения чувствительных к эстрогенам заболеваний
RU2219167C2 (ru) N-замещенные аминотетралины как лиганды для рецептора y5 нейропептида y, полезные при лечении ожирения и других расстройств
KR880011199A (ko) 신규 펩타이드 화합물, 그의 제조방법 및 그를 함유하는 약학적 조성물
KR920008065A (ko) 펩타이드 화합물, 그의 제조 방법 및 그를 함유하는 약제학적 조성물
KR960034164A (ko) 스틸벤 유도체 및 이를 함유하는 약제학적 조성물
KR930019655A (ko) 종양치료 조성물 및 치료방법
KR890005124A (ko) 세펨 화합물 및 이의 제조방법
HUT61780A (en) Process for producing new peptides and pharmaceutical compositions comprising same as active ingredient
AR003138A1 (es) Composicion farmaceutica para tratar canceres y virus con (1h-1,2,4- triazoles) y composicion de unidad de dosis que la comprende
JP2000159790A5 (ko)
KR900009606A (ko) 불소-함유 2-니트로 이미다졸 유도체 및 그를 함유하는 방사선 증감제
ATE81655T1 (de) Cephemverbindungen und verfahren zu ihrer herstellung.
DE69330601T2 (de) Serotoninergische ergolin derivate
KR900011724A (ko) 특정 피롤릴페닐-치환된 하이드록삼산 유도체
RU95107655A (ru) Глюкопиранозидбензотиофены, способ получения, фармацевтическая композиция
KR920002517A (ko) 칼모둘린 억제 특성을 갖는 벤즈히드릴 유도체 및 그의 제조방법
HUT72078A (en) Diarylalkyl piperidines useful as multi-drug resistant tumor agents and pharmaceutical compositions containing the compounds
RU94032285A (ru) Цефалоспориновые соединения, способ их получения, фармацевтическая композиция
KR960700711A (ko) 뇌혈관성 질환의 치료 또는 예방용 약제(Medicament for treating or preventing cerebrovascular diseases)
KR890008148A (ko) 새로운 세파로스포린 화합물 및 항균제
KR930000523A (ko) 신규한 세펨 화합물
KR920005719A (ko) 라브단 및 이의 제조방법
KR910009286A (ko) 약제학적 제제
KR980002033A (ko) 트리아졸 유도체 또는 그 염

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application